STOCK TITAN
  1. Home
  2. Sec-filings
  3. RXRX
  4. [144] RECURSION PHARMACEUTICALS, INC. SEC Filing

Ex-Recursion (NASDAQ: RXRX) director plans new sale after 340K-share June trade

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

RECURSION PHARMACEUTICALS, INC. (RXRX) is the issuer of Class A common stock covered by this Rule 144 notice. Former director Christopher C. Gibson has filed to sell 77,290 Class A shares through Fidelity Brokerage Services LLC, with an aggregate market value of $262,013.10, listed on NASDAQ. The notice also lists multiple Class A share sales over the prior three months by Gibson, the Gibson Family Trust, and Lahwran-3 LLC, for which Gibson is an authorized individual or trustee.

Positive

  • None.

Negative

  • None.
Shares to be sold 77,290 shares of Class A common stock Proposed sale under Rule 144
Aggregate market value $262,013.10 Market value of 77,290 Class A shares to be sold
CUSIP 535342170 Identifier for RXRX Class A common stock
Proposed sale date 08/21/2026 Date of proposed Rule 144 sale
Prior sale on 05/22/2026 40,000 shares for $123,200.00 Class A shares sold by Christopher C. Gibson
Prior sale on 06/18/2026 340,440 shares for $1,089,541.29 Class A shares sold by Christopher C. Gibson
Prior sale on 07/07/2026 by Lahwran-3 LLC 100,000 shares for $390,028.63 Class A shares sold via associated LLC
Prior sale on 07/07/2026 by Gibson Family Trust 50,000 shares for $195,014.41 Class A shares sold via associated trust
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Founders Shares financial
"Class A | 04/20/2021 | Founders Shares | Issuer"
Founders shares are a special block of a company’s stock originally given to the people who started the business; they often carry extra voting power or favorable terms compared with regular shares. For investors, these shares matter because they concentrate control and influence how future funding, ownership dilution, and decision-making will play out—think of founders shares as the steering wheel that can steer a company’s direction even as more passengers (investors) climb aboard.
attorney-in-fact regulatory
"as attorney-in-fact for Christopher Gibson"
An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.
aggregate market value financial
"77290 | 262013.10 | 535342170 | 08/21/2026"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

What securities are being proposed for sale under Rule 144 for RXRX?
The notice covers a proposed sale of 77,290 shares of Class A common stock of RECURSION PHARMACEUTICALS, INC. (RXRX). The filing reports an aggregate market value of $262,013.10 for these shares, to be sold on NASDAQ.

Who is the selling security holder in this RXRX Form 144 filing?
The selling security holder is Christopher C. Gibson, identified as a former director of RECURSION PHARMACEUTICALS, INC. The filing is submitted on his behalf, with Fidelity Brokerage Services LLC acting as the broker and attorney-in-fact signing the notice.

Which broker is handling the proposed RXRX share sale for Christopher C. Gibson?
The proposed sale of RXRX Class A shares is to be executed through Fidelity Brokerage Services LLC. The Form 144 is signed “/s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Christopher Gibson.”

What prior RXRX share sales by Christopher C. Gibson are disclosed in the past three months?
The notice lists numerous prior Class A sales, including 40,000 shares on 05/22/2026 for $123,200.00 and 340,440 shares on 06/18/2026 for $1,089,541.29, along with multiple additional transactions through August 20, 2026.

Are any entities associated with Christopher C. Gibson included in the RXRX past 3-month sales?
Yes. The filing states that past three-month sales include trades from the Lahwran-3 LLC account, where Christopher C. Gibson is an authorized individual and account stakeholder, and the Gibson Family Trust, where he is a trustee and account stakeholder.

When is the stated date of sale and notice date for this RXRX Form 144?
The proposed sale of 77,290 RXRX Class A shares is dated for 08/21/2026 in the securities information section. The Date of Notice is also listed as 08/21/2026 at the signature section of the Form 144.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR